NASDAQ:NCNA

NuCana Q1 2026 Earnings Results & Report

NuCana logo
$0.88 +0.02 (+1.96%)
Closing price 03:55 PM Eastern
Extended Trading
$0.87 -0.01 (-0.80%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NuCana beat analyst earnings expectations in its Q1 2026 results, released May 15, 2026. The company reported EPS of -$1.25 versus the -$2.6440 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens

NuCana EPS Results

Actual EPS
-$1.25
Consensus EPS
-$2.6440
Beat/Miss
Beat by +$1.3940
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 5 quarters

NuCana Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

NuCana Q1 2026 Earnings FAQ

NuCana (NASDAQ:NCNA) reported earnings of -$1.25 per share for Q1 2026, beating the consensus estimate of -$2.6440. The report was announced on Friday, May 15, 2026.

NuCana Earnings Headlines

Don't lose access to this
Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.tc pixel
NuCana plc Sponsored ADR
See More NuCana Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NuCana? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NuCana and other key companies, straight to your email.

About NuCana

NuCana (NASDAQ:NCNA) is a clinical-stage biopharmaceutical company based in Edinburgh, Scotland, that develops investigational medicines for cancer. Its research focuses on nucleotide analogues, a class of compounds used in some cancer treatments.

The company’s ProTide platform is designed to improve how these compounds enter cells and become active. NuCana’s development programs have included NUC-3373, an investigational fluoropyrimidine, and NUC-7738, an investigational adenosine analogue, as well as NUC-1031, an earlier candidate.

NuCana’s work is centered on developing and evaluating potential cancer therapies; its drug candidates are investigational and have not been established as approved treatments.

View NuCana Profile